This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
This webinar will describe the Translational Pharmaceutics platform and present Enabled-First-in-Human case studies to illustrate how it has been applied in early stage drug development programs. There will be two live broadcasts on Wednesday July 9, 2014, at 9am EDT/2pm BST, and at 12pm EDT/5pm BST.
Toronto, Canada (PRWEB) June 25, 2014
Enabled-First-in-Human programs re-engineer the pathway from candidate selection into clinical development and through to Proof of Concept (PoC). Timelines for early development can be significantly accelerated and the associated costs reduced, supporting pharma development teams in their quest for ever increasing R&D efficiency and productivity.
Enabled-First-in-Human programs exploit Quotients Translational Pharmaceutics platform, which integrates real-time drug product manufacturing with clinical testing. This platform delivers:
Join speakers, Alyson Connor, Director of Exploratory Clinical Pharmacology at Quotient Clinical, and Phil Collis, Vice President of Clinical Development at Biocryst Pharmaceuticals, for an informative session that will include a Q&A with the audience.
For more information or to register for this webinar, visit: Enabled-First-in-Human Accelerating Your Programs into Clinic and Through to Proof of Concept (PoC)
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Tel: +1 (416) 977-6555 ext 352
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/06/prweb11966812.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.